Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 4/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.47 |
| ▸ | CDK2 | P24941 | 9/20 | 0.47 |
| ▸ | CDK1 | P06493 | 5/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.47 |
| ▸ | PAK4 | O96013 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900939 | 1.00 | FLT3 (0.48) | FLT3PDGFRACCNE1CDK2CDK1 | |
| SCHEMBL4894170 | 0.88 | FLT3 (0.60) | FLT3PDGFRACCNE1CDK2CDK1 | |
| SCHEMBL4894184 | 0.88 | FLT3 (0.60) | FLT3PDGFRACCNE1CDK2CDK1 | |
| SCHEMBL5840595 | 0.82 | CDK1 (0.62) | FLT3PDGFRACCNE1CDK2CDK1 | |
| SCHEMBL5840603 | 0.82 | CDK1 (0.62) | FLT3PDGFRACCNE1CDK2CDK1 | |
| SCHEMBL4897255 | 0.81 | ADORA3 (0.51) | FLT3PDGFRACCNE1CDK2CDK1 | |
| SCHEMBL4899194 | 0.81 | FLT3 (0.48) | FLT3PDGFRACCNE1CDK2CDK1 | |
| SCHEMBL4899218 | 0.81 | FLT3 (0.48) | FLT3PDGFRACCNE1CDK2CDK1 | |
| SCHEMBL4897230 | 0.81 | ADORA3 (0.51) | FLT3PDGFRACCNE1CDK2CDK1 | |
| SCHEMBL5891718 | 0.80 | FLT3 (0.53) | FLT3PDGFRACCNE1CDK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041824-B2 | Purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | claimed |
| US-20040063732-A1 | Novel purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2004-04-01 | — | — | US | claimed |
| US-20080090849-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | AVENTIS PHARMA S.A. (FR) | 2008-04-17 | — | — | US | disclosed |
| US-7041824-B2 | Purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | disclosed |
| US-20040063732-A1 | Novel purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063732-A1 | Novel purine derivatives, preparation method and use as medicines | CDK1, CDK6, PNP | FLT3 528/4885PDGFRA 2734/4885CCNE1 108/4885 |
| US-20080090849-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | CDK1, CDK6, PNP | FLT3 406/4885PDGFRA 2297/4885CCNE1 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.